Haemonetics gets plasma separation approval:
This article was originally published in Clinica
The US FDA has approved Haemonetics' leucocyte apheresis protocol. The approval will allow users of the company's PCS2 blood processing system to separate 130-155 ml of leucocytes at the same time as producing 450-750 ml of plasma from donor blood.
You may also be interested in...
As the coronavirus continues to spread, one of the big four global vaccines companies has committed itself to the fight.
Sweden’s mid-sized pharmaceutical company, Swedish Orphan Biovitrum, has expanded into hematology and strengthened its immunology business, growing its top and bottom lines in 2019.